Literature DB >> 26167250

Relevance of ADAMTS13 to liver transplantation and surgery.

Saiho Ko1, Hisanao Chisuwa1, Masanori Matsumoto1, Yoshihiro Fujimura1, Eiji Okano1, Yoshiyuki Nakajima1.   

Abstract

A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13 (ADAMTS13) specifically cleaves unusually-large von Willebrand factor (VWF) multimers under high shear stress, and down-regulates VWF function to form platelet thrombi. Deficiency of plasma ADAMTS13 activity induces a life-threatening systemic disease, termed thrombotic microangiopathy (TMA) including thrombotic thrombocytopenic purpura (TTP). Children with advanced biliary cirrhosis due to congenital biliary atresia sometimes showed pathological features of TMA, with a concomitant decrease of plasma ADAMTS13 activity. Disappearance of their clinical findings of TTP after successful liver transplantation suggested that the liver is a major organ producing plasma ADAMTS13. In situ hybridization analysis showed that ADAMTS13 was produced by hepatic stellate cells. Subsequently, it was found that ADADTS13 was not merely responsible to development of TMA and TTP, but also related to some kinds of liver dysfunction after liver transplantation. Ischemia-reperfusion injury and acute rejection in liver transplant recipients were often associated with marked decrease of ADAMTS13 and concomitant formation of unusually large VWF multimers without findings of TMA/TTP. The similar phenomenon was observed also in patients who underwent hepatectomy for liver tumors. Imbalance between ADAMTS13 and VWF in the hepatic sinusoid might cause liver damage due to microcirculatory disturbance. It can be called as "local TTP like mechanism" which plays a crucial role in liver dysfunction after liver transplantation and surgery.

Entities:  

Keywords:  A disintegrin-like and metalloproteinase with thrombospondin type-1 motifs 13; Acute rejection; Hepatectomy; Ischemia-reperfusion injury; Liver dysfunction; Liver surgery; Liver transplantation; Local thrombotic thrombocytopenic purpura like mechanism; Microcirculation; Thrombocytopenia; von Willebrand factor

Year:  2015        PMID: 26167250      PMCID: PMC4491906          DOI: 10.4254/wjh.v7.i13.1772

Source DB:  PubMed          Journal:  World J Hepatol


  54 in total

1.  Development of ADAMTS13 inhibitor in a patient with hepatitis C virus-related liver cirrhosis causes thrombotic thrombocytopenic purpura.

Authors:  Masato Yagita; Masahito Uemura; Takefumi Nakamura; Akane Kunitomi; Masanori Matsumoto; Yoshihiro Fujimura
Journal:  J Hepatol       Date:  2005-03       Impact factor: 25.083

2.  Effect of severe thrombocytopenia on patient outcome after liver transplantation.

Authors:  Chaker Ben Hamida; Jean-Yves Lauzet; Saida Rézaiguia-Delclaux; Christophe Duvoux; Daniel Cherqui; Philippe Duvaldestin; François Stéphan
Journal:  Intensive Care Med       Date:  2003-04-03       Impact factor: 17.440

3.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

4.  Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.

Authors:  M Furlan; R Robles; M Solenthaler; M Wassmer; P Sandoz; B Lämmle
Journal:  Blood       Date:  1997-05-01       Impact factor: 22.113

Review 5.  Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura.

Authors:  Karen K Swisher; Deirdra R Terrell; Sara K Vesely; Johanna A Kremer Hovinga; Bernhard Lämmle; James N George
Journal:  Transfusion       Date:  2009-02-06       Impact factor: 3.157

6.  Outcome of orthotopic liver transplantation in patients with haemophilia.

Authors:  F H Gordon; P K Mistry; C A Sabin; C A Lee
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

7.  Interleukin 1 or endotoxin increases the release of von Willebrand factor from human endothelial cells.

Authors:  A E Schorer; C F Moldow; M E Rick
Journal:  Br J Haematol       Date:  1987-10       Impact factor: 6.998

8.  Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13).

Authors:  Barbara Plaimauer; Klaus Zimmermann; Dirk Völkel; Gerhard Antoine; Randolf Kerschbaumer; Pegah Jenab; Miha Furlan; Helen Gerritsen; Bernhard Lämmle; Hans Peter Schwarz; Friedrich Scheiflinger
Journal:  Blood       Date:  2002-07-12       Impact factor: 22.113

9.  ADAMTS13 activity to antigen ratio in physiological and pathological conditions associated with an increased risk of thrombosis.

Authors:  Hendrik B Feys; Maria T Canciani; Flora Peyvandi; Hans Deckmyn; Karen Vanhoorelbeke; Pier M Mannucci
Journal:  Br J Haematol       Date:  2007-06-29       Impact factor: 6.998

Review 10.  Hypercoagulation and thrombophilia in liver disease.

Authors:  P G Northup; V Sundaram; M B Fallon; K R Reddy; R A Balogun; A J Sanyal; Q M Anstee; M R Hoffman; Y Ikura; S H Caldwell
Journal:  J Thromb Haemost       Date:  2007-09-24       Impact factor: 5.824

View more
  7 in total

1.  Plasma von Willebrand factor levels predict in-hospital survival in patients with acute-on-chronic liver failure.

Authors:  K S Prasanna; Ashish Goel; G Jayakumar Amirtharaj; Anup Ramachandran; K A Balasubramanian; Ian Mackie; Uday Zachariah; K G Sajith; Elwyn Elias; C E Eapen
Journal:  Indian J Gastroenterol       Date:  2016-11-08

Review 2.  Ischaemia reperfusion injury in liver transplantation: Cellular and molecular mechanisms.

Authors:  Wasim A Dar; Elise Sullivan; John S Bynon; Holger Eltzschig; Cynthia Ju
Journal:  Liver Int       Date:  2019-04-02       Impact factor: 5.828

3.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

4.  Elevated ADAMTS13 Activity is Associated with Poor Postoperative Outcome in Patients Undergoing Liver Resection.

Authors:  Stefanie Haegele; Jennifer Fuxsteiner; David Pereyra; Christoph Koeditz; Benedikt Rumpf; Clara Schuetz; Christian Schwarz; Christine Brostjan; Thomas Gruenberger; Patrick Starlinger
Journal:  Sci Rep       Date:  2018-11-14       Impact factor: 4.379

5.  Increasing plasma ADAMTS13 activity is associated with HBeAg seroconversion in chronic hepatitis B patients during 5 years of entecavir treatment.

Authors:  Renyong Guo; Yirui Xie; Jiezuan Yang; Haifeng Lu; Ping Ye; Linfeng Jin; Wenqin Lin
Journal:  Sci Rep       Date:  2019-04-11       Impact factor: 4.379

Review 6.  Inflammation, von Willebrand factor, and ADAMTS13.

Authors:  Junmei Chen; Dominic W Chung
Journal:  Blood       Date:  2018-06-04       Impact factor: 25.476

7.  Impedance Aggregometry Reveals Increased Platelet Aggregation during Liver Transplantation.

Authors:  Mohamed Soliman; Matthias Hartmann
Journal:  J Clin Med       Date:  2019-10-27       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.